Retatrutide — Research Overview

A triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, producing the broadest hormonal coverage of any GLP-1 class compound currently in trials. Phase 2 clinical trial data has shown retatrutide to produce the largest weight-loss results documented in metabolic research to date.

Back to Peptide Encyclopedia